We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MedImmune Licenses BioWa’s POTELLIGENT™ Technology
News

MedImmune Licenses BioWa’s POTELLIGENT™ Technology

MedImmune Licenses BioWa’s POTELLIGENT™ Technology
News

MedImmune Licenses BioWa’s POTELLIGENT™ Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MedImmune Licenses BioWa’s POTELLIGENT™ Technology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioWa, Inc. has announced that MedImmune, Inc. has licensed BioWa's POTELLIGENT™ technology for use in researching and developing select MedImmune antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).

"We are delighted that MedImmune, a recognized biotechnology leader, has decided to use our POTELLIGENT™ technology as a method for maximizing the potential of therapeutic antibodies," said Dr. Nobuo Hanai, BioWa President and CEO.

"We believe that this collaboration with MedImmune highlights the potential advantages of our ADCC-enhancing technology and furthers BioWa's goal to bring about safe and more effective treatments for cancer and other life-threatening and debilitating diseases."

Under the terms of the agreement, BioWa will provide MedImmune with non- exclusive commercial rights to use the technology to enhance ADCC in developing antibodies for multiple targets.

In return, BioWa will receive technology access fees, and may receive milestone payments and royalties on products developed by MedImmune.

Advertisement